Brain-Derived Neurotrophic Factor (BDNF) levels were affected by aging. Brain BDNF levels were known to decrease along with advanced age thus correlated with any diseases such as cognitive impairment and Alzheimer. Mesenchymal Stem Cell (MSC) is one of the potential modalities actively investigated against age-related diseases. This study evaluated the effect of human MSC administration to brain BDNF levels in aged rats. Intravenous injection of 10 million per body weight human MSC were given four times in 3 months interval to 22-24 months old female and male Spraque-Dawley rats. As control group, aged rats were injected by normal saline at the same volume and frequencies. Moreover, young 3-6 months rats also examined as negative control. By the end of the experiment, we analyzed three rats from each group. Brain BDNF levels were measured by enzyme-linked immunosorbent assay and normalize to the protein levels. One-way ANOVA and LSD post hoc analysis was performed to compare the differences between groups. BDNF levels in male appeared similar between young, aged, and MSC treated groups. Meanwhile, control aged female groups had significantly lower BDNF levels compared to young (p = 0.019) and MSC-treated aged rats (p = 0.001). There was no difference of BDNF levels between young and MSC-treated aged in female rats (p = 0,068). Both sex had similar BDNF levels (p = 0.249) in control-aged groups. In contrast, female young and MSC-treated aged rats achieved significantly higher BDNF levels (p = 0.009 and p <0.001) compared to the male groups, respectively. These results suggest that human mesenchymal stem cell intravenous injection can increase brain BDNF levels in female aged rats.
INTRODUCTION

One of the major molecules in ageing is
Brain-Derived Neurotrophic Factor (BDNF).
Study in human suggested that plasma BDNF is a biomarker of impaired memory and general cognitive function in ageing women (Komulainen et al, 2008) . BDNF is highly expressed in brain areas demonstrating functional plasticity (Tapia-Arancibia et al, 2008 ). Brain BDNF levels were known to decrease along with advanced age thus correlated with any diseases such as cognitive impairment and Alzheimer (Budni et al, 2015) .
Cognitive defects associated with aging might be related to BDNF system (Calabrese, 2013) .
Restoring BDNF levels may be promising therapeutic target in preventing age-related diseases. Mesenchymal Stem Cell (MSC) role in aging was being enormously investigated against age-related diseases. Human adipose tissuederived MSC (ADMSCs) intravenous injection in aged male ICR mice (18-month-old) able to restore whole brain BDNF levels and showed cognitive improvement (Park et al, 2013) .
Human amniotic membrane-derived MSC and
ADMSCs injection in 10-month-old male F344 rats elongate health span and life span along with neurotrophic factors recovery (Kim et al, 2015) .
Another source of MSC, Wharton-Jelly (WJ) MSC, which is easier to obtain may also has promising potential advantage for treatment of age-related diseases.
In human studies, plasma BDNF associated with general cognitive decline in ageing women but not in men (Komulainen et al, 2008) . Moreover, Chan and Ye (2017) considered sex influences in BDNF levels on sex hormones, which were able to modulate the activities of BDNF. Thus, evaluating BDNF in both sexes might be valuable. This study evaluated the effect of human WJ-MSC administration to brain BDNF levels in female and male aged rats. 
METHODS
RESULTS
At the end of our experiment, the mortality rate of the WJ-MSC treatment groups was high. Thus in this report, we analyzed one of the WJ-MSC treatment groups dose 10 7 per kg body weight four times at 3-month intervals. We evaluated three rats from each group.
A. B. Moreover, there also a link between BDNF expression and housing of the rats as explained by Murinova et al (2017) .
CONCLUSION
In conclusion, WJ-MSC intravenous injection increased brain BDNF levels in female aged rats.
